Research programme: dual action antithrombotic therapeutics - Endotis Pharma

Drug Profile

Research programme: dual action antithrombotic therapeutics - Endotis Pharma

Alternative Names: EP 224283; Org 224283

Latest Information Update: 02 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Organon
  • Developer Endotis Pharma
  • Class Antithrombins; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors; GPIIb-IIIa antagonists; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 23 Apr 2009 Preclinical development is ongoing France
  • 01 Nov 2007 Antithrombotic compounds licensed to Endotis Pharma worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top